COMMUNIQUÉS West-GlobeNewswire

Bavarian Nordic A/S - Articles of Association
11/07/2017
Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The [...]
uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
11/07/2017
-- Findings Further Support Expanding the Eligibility of AAV5 Gene Therapies to Nearly All Patients with Hemophilia B -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. ( [...]
Össur hf: Q2 2017 Results - Conference call Wednesday 26 July
11/07/2017
Announcement from Össur hf. no: 49/2017 Conference call on Wednesday 26 July at 9:00 CET / 7:00 GMT / 3:00 EDT After market closing on Tuesday 25 July, Össur will publish its financial results for Q2 2017. On Wednesday [...]
Vistin Pharma ASA : Vistin Pharma announces the sale of its Opioids and CMO business
11/07/2017
Oslo, Norway, 11 July 2017 Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma" or "Company") announced today that the Company has entered a Sales and Purchase agreement with TPI Enterprises Limited ("TPE [...]
Labiaplasty Is the World's Fastest Growing Cosmetic Surgery Procedure, International Study Reports
11/07/2017
An International Study Conducted by the International Society of Aesthetic Plastic Surgery Reveals Significant Growth in Labiaplasty as More Women Choose to Change the Appearance of Their Genital Area NEW YORK, July 11 [...]
NEOVACS : Le Comité Indépendant de Surveillance des Données et de la Tolérance confirme le bon déroulement de l'essai clinique de phase IIb dans le lupus
11/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Le Comité Indépendant de Surveillance des Données et de la Tolérance (iDSMB) confirme le bon déroulement de l'essai clinique de phase IIb dans le lupus avec l'IFNalpha [...]
Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
11/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus Third positive data review by IDSMB follows completion of patient [...]
Sanofi to acquire Protein Sciences
11/07/2017
Sanofi to acquire Protein Sciences - Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio - Paris, France - July 11, 2017 - Sanofi announced today it will acquire Protein Sciences, a [...]
Sanofi sur le point d'acquérir Protein Sciences
11/07/2017
Sanofi sur le point d'acquérir Protein Sciences - Cette acquisition permettra à Sanofi Pasteur d'enrichir son portefeuille d'un vaccin antigrippal recombinant - Paris, France - Le 11 juillet 2017 - Sanofi annonce [...]
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
10/07/2017
Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Months of Follow-Up Second-dose Cohort Demonstrates Dose Response Up to One Year, with 84% Reduction in Spontaneous Bleeds and All [...]
Ossur Hf : Transactions in relation to share buyback program
10/07/2017
Announcement from Össur hf. No. 48/2017 Reykjavík, 10 July 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Sanofi : Disclosure of trading in own shares
10/07/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
10/07/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
GENFIT : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC
10/07/2017
GENFIT : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC Lille (France), Cambridge (Massachusetts, Etats-Unis), le 10 juillet 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique [...]
GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC
10/07/2017
GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC Lille (France), Cambridge (Massachusetts, United States), July 10, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the [...]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
10/07/2017
Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) [...]
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
10/07/2017
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors - With up [...]
Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients...
10/07/2017
Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients atteints d'hémophilie A [...]
AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
10/07/2017
Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates on the advancement of [...]

Pages